Seasonal influenza causes millions of infections and tens of thousands of deaths annually in the United States, posing a significant public health challenge12. Rapid and accurate diagnosis is essential to enable timely treatment and reduce transmission. The rise of at-home testing, accelerated by the COVID-19 pandemic, offers new opportunities for influenza detection outside clinical settings34. However, questions remain about the accuracy and accessibility of at-home flu tests compared to traditional clinical diagnostics52.
At-Home Flu Test Accuracy
At-home flu tests primarily use rapid diagnostic tests (RDTs) that detect influenza viral antigens. These antigen-based tests generally have moderate sensitivity but high specificity, meaning they are good at confirming when someone does not have the flu but less reliable at detecting all true positive cases67. Sensitivities for influenza RDTs typically range from 50% to 70%, with specificities above 90%68. In contrast, molecular tests such as polymerase chain reaction (PCR) assays are considered the gold standard due to their near-perfect sensitivity and specificity69.
A large prospective study involving over 600 participants in the Seattle area evaluated the accuracy of an at-home influenza RDT compared with laboratory PCR testing of self-collected nasal swabs101112. The study found that the at-home rapid test had an overall sensitivity of approximately 61% and specificity of 95%, comparable to rapid tests used in clinical settings1012. False-negative results were more common when testing occurred beyond 72 hours after symptom onset, highlighting the importance of early testing for optimal accuracy13812.
Additional research confirms that self-collected nasal swabs and self-administered rapid tests at home yield accuracy similar to those performed by healthcare professionals1014. However, antigen-based tests remain less sensitive than molecular assays, which detect viral genetic material and can identify infections even with lower viral loads6915.
The timing of testing is critical. Influenza viral shedding peaks within the first 48 to 72 hours of illness, and rapid tests are most sensitive during this window138. Sensitivity declines as time from symptom onset increases, leading to more false negatives138. Therefore, individuals are advised to test as soon as symptoms appear to maximize detection chances15.
“Home tests are a valuable tool to support the management of influenza and other respiratory infections.”
— Matthew J. Thompson, University of Washington School of Medicine2
Several at-home flu and COVID-19 combination antigen tests have recently become available, offering rapid results within 10 to 15 minutes51617. These tests show high specificity and moderate sensitivity. For example, the Healgen Rapid Check COVID-19/Flu A&B Antigen Test demonstrated positive agreement rates of approximately 90-92% for influenza A and B and over 99% negative agreement in clinical studies1718. Despite these promising results, a negative antigen test does not fully exclude influenza infection, and follow-up testing or clinical evaluation may be warranted if symptoms persist71517.
Molecular at-home tests, such as the Lucira COVID-19 & Flu Home Test, offer higher sensitivity and specificity comparable to laboratory PCR but are less widely available and more expensive, costing around $50 to $80 per test1518. Unfortunately, some molecular at-home combo tests have been discontinued due to manufacturer issues, limiting current availability15.
- Rapid antigen tests at home have sensitivities around 50-70% and specificities above 90%, similar to clinical rapid tests6812.
- Molecular tests (PCR-based) provide higher accuracy but are less accessible for at-home use6915.
- Testing within 48 to 72 hours of symptom onset yields the highest sensitivity13812.
- False negatives are more common with antigen tests, especially if testing is delayed or sampling is inadequate13815.
- At-home self-swabbing and testing can be as accurate as clinician-administered tests when instructions are followed1014.
At-Home Flu Test Availability
Despite the clear public health benefits of rapid influenza diagnosis, at-home flu tests have historically lagged behind other infectious disease diagnostics due to regulatory, technical, and market challenges419. Before the COVID-19 pandemic, consumer demand for home infectious disease testing was low, and commercial interest in developing such tests was limited19. The pandemic, however, accelerated innovation and public acceptance of at-home testing technologies, creating a more favorable environment for respiratory virus self-tests34.
Currently, no fully authorized at-home flu tests are widely available on store shelves in the United States outside of emergency use authorizations (EUAs) or limited marketing authorizations418. The only FDA-approved over-the-counter (OTC) at-home diagnostic test besides COVID-19 tests is an HIV test approved in 2012419. However, several at-home combination tests detecting both influenza and SARS-CoV-2 have recently gained FDA emergency use authorization and are becoming more accessible161718.
Early testing within 48 to 72 hours of symptom onset significantly improves the accuracy of at-home flu tests, especially antigen-based ones. Prompt diagnosis allows for timely antiviral treatment, which is most effective when started early. Delayed testing increases the risk of false negatives and missed opportunities to reduce transmission.121315178
The COVID-19 pandemic disrupted clinical validation studies for influenza tests due to reduced flu circulation and resource reallocation, delaying the approval and market entry of new at-home flu diagnostics34. Nevertheless, companies are actively developing multiplex tests that can simultaneously detect influenza A, influenza B, and COVID-19, aiming to improve convenience and diagnostic accuracy during respiratory virus seasons20421.
These combination tests are now available at major pharmacies and online retailers, typically priced around $10 to $15 per test1615. While insurance coverage for at-home flu tests varies, health savings accounts (HSAs) and flexible spending accounts (FSAs) may help offset costs15. Molecular at-home tests remain less common and more expensive, limiting widespread consumer access15.
Public health experts emphasize that home-based flu testing could significantly reduce the influenza burden by enabling faster diagnosis, earlier isolation, and prompt antiviral treatment, which can shorten illness duration and severity223. The increased availability of accurate and affordable at-home flu tests is expected to improve patient outcomes and reduce transmission in communities216.
- Regulatory hurdles and validation challenges have slowed the approval of at-home flu tests419.
- The COVID-19 pandemic increased public interest and acceptance of home testing but disrupted flu test development34.
- Multiplex tests combining flu and COVID-19 detection are emerging and gaining market presence201621.
- At-home antigen flu tests are now available OTC at pharmacies and online, priced around $10-$15 per test1615.
- Molecular at-home flu tests are less available and more costly, with some products discontinued1518.
| Test Type | Sensitivity | Specificity | Availability | Cost Range |
|---|---|---|---|---|
| Rapid Antigen | 50-70%68 | >90%68 | Widely available OTC1615 | $10-$15 per test15 |
| Molecular (PCR) | >90%239 | >95%239 | Limited, some discontinued1518 | $50-$80 per test15 |
